

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

# Determinants of health as predictors for differential antibody responses following SARS-CoV-2 primary and booster vaccination in an at-risk, longitudinal cohort

Felipe Echeverri Tribin<sup>3,4†</sup>, Erin Williams<sup>1,3†</sup>, Valeska Testamarck<sup>5</sup>, Juan Manuel Carreño<sup>7,8</sup>, Dominika Bielak<sup>7</sup>, Temima Yellin<sup>7</sup>, Florian Krammer<sup>7,8,9</sup>, Michael Hoffer<sup>1,5</sup>, Suresh Pallikkuth<sup>2</sup>, and Savita Pahwa<sup>2</sup>

<sup>1</sup> Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, 33136 USA

<sup>2</sup> Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, 33146, USA

<sup>3</sup> Department of Biomedical Engineering, University of Miami, Miami, Florida, 33136, USA

<sup>4</sup> University of Miami Miller School of Medicine, Miami, Florida, 33136, USA

<sup>5</sup> Indiana University School of Medicine, Indianapolis, IN 46202, USA

<sup>6</sup> Department of Neurological Surgery, University of Miami, Miller School of Medicine, Miami, Florida, 33136, USA

<sup>7</sup> Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, 10029, USA

<sup>8</sup>Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA

<sup>9</sup>Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

\*Corresponding author

E-mail: [spahwa@med.miami.edu](mailto:spahwa@med.miami.edu) (SP)

† These authors contributed equally to this work.

## 32 **Abstract**

33 Post vaccine immunity following COVID-19 mRNA vaccination may be driven by extrinsic, or  
34 controllable and intrinsic, or inherent health factors. Thus, we investigated the effects of extrinsic and  
35 intrinsic on the peak antibody response following COVID-19 primary vaccination and on the trajectory of  
36 peak antibody magnitude and durability over time. Participants in a longitudinal cohort attended visits every  
37 3 months for up to 2 years following enrollment. At baseline, participants provided information on their  
38 demographics, recreational behaviors, and comorbid health conditions which guided our model selection  
39 process. Blood samples were collected for serum processing and spike antibody testing at each visit. Cross-  
40 sectional and longitudinal models (linear-mixed effects models) were generated to assess the relationship  
41 between selected intrinsic and extrinsic health factors on peak antibody following vaccination and to  
42 determine the influence of these predictors on antibody over time. Following cross-sectional analysis, we  
43 observed higher peak antibody titers after primary vaccination in females, those who reported recreational  
44 drug use, younger age, and prior COVID-19 history. Following booster vaccination, females and Hispanics  
45 had higher peak titers after the 3<sup>rd</sup> and 4<sup>th</sup> doses, respectively. Longitudinal models demonstrated that  
46 Moderna mRNA-1273 recipients, females, and those previously vaccinated had increased peak titers over  
47 time. Moreover, drug users and half-dose Moderna mRNA-1273 recipients had higher peak antibody titers  
48 over time following the first booster, while no predictive factors significantly affected post-second booster  
49 antibody responses. Overall, both intrinsic and extrinsic health factors play a significant role in shaping  
50 humoral immunogenicity after initial vaccination and the first booster. The absence of predictive factors  
51 for second booster immunogenicity suggests a more robust and consistent immune response after the second  
52 booster vaccine administration.

53

54 Key Words: "SARS-CoV-2", "primary vaccination", "booster vaccination", "humoral immunogenicity",  
55 "breakthrough", "cross-sectional analysis", "linear mixed-effects models"

## 57 **Introduction**

58 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has had rapid and widespread  
59 international effects since its onset in late December 2019 (1-5). Aside from the socioeconomic burdens  
60 and turmoil generated from its spread, early access to health interventions and prophylactic measures for  
61 the virus were limited and ineffective at controlling the spread. Instead, government-imposed lockdowns  
62 and social distancing were utilized as preventative measures (4), but due to high transmissibility and  
63 virulence the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for  
64 nearly 400 coronavirus disease-19 (COVID-19) related medical products in the United States, including  
65 diagnostic tests, medical devices, drugs, and vaccines (4, 6-8), and helped distribute vaccines worldwide.

66  
67 Prior work has shown that post-vaccine immunity is driven by various factors, including prior SARS-CoV-2  
68 infection, vaccine manufacturer, heterologous booster administration, time since vaccination, and the  
69 magnitude of peak antibody titers after vaccination (9-18). Furthermore, both systemic and local symptoms  
70 following SARS-CoV-2 infection and vaccination have been associated with higher peak antibody  
71 responses following primary vaccination (5). Overall, COVID-19 vaccines and boosters have been  
72 demonstrated to safely curb infection and severe SARS-CoV-2 outcomes, but more work is needed to  
73 understand drivers for post-vaccination heterogeneity. The effect of intrinsic health factors (IHF) and  
74 extrinsic health factors (EHF) on COVID-19 vaccine immunogenicity is unknown. IHFs are  
75 characteristics that relate to an individual and cannot be changed or manipulated (e.g., age, biological sex,  
76 or race), while EHF relate to health comorbidities and behaviors (e.g., diet, smoking, or drug consumption)  
77 that can be altered or controlled.

78  
79 Accounting for IHFs and EHF when evaluating post-vaccine immunogenicity in large populations could  
80 result in more personalized analyses from a public health approach (5). For example, prior research has  
81 shown that individuals with diabetes mellitus and obesity exhibit dampened immune responses to COVID-

82 19 and hepatitis B vaccines, compared to controls (19, 20). Apart from chronic disease, age, and biological  
83 sex, human leukocyte antigen types have also been identified as factors that can cause heterogeneous  
84 immune reactions to vaccination due to senescence and variable cytokine production among different  
85 groups (21-24). Despite these findings, the evaluation of IHFs and EHF have yet to be determined in a  
86 longitudinal cohort following COVID-19 vaccination. Thus, the purpose of this study is to investigate the  
87 effects of IHFs and EHF on peak antibody (Ab) titers following COVID-19 primary vaccination (PV) and  
88 booster vaccination (BV), and to investigate how these factors influence Ab magnitude and trajectory over  
89 time.

90

## 91 **Methods**

### 92 **Study design**

93 Participants were enrolled in our Institutional Review Board (IRB) approved (#20201026), longitudinal,  
94 observational SARS-CoV-2 immunity study (n=228) known as “CITY” (COVID-19 ImmuniTY study) as  
95 part of the PARIS/SPARTA study (25). Recruitment for the study began in October 2020 and ended in  
96 February 2023. The study was conducted at the University of Miami Miller School of Medicine, and study  
97 subjects participated in visits every 3 months for a total of 2 years from the time of enrollment. The primary  
98 objective of the CITY study was to characterize differential antibody kinetics among SARS-CoV-2  
99 uninfected and infected individuals in a high-risk, ethnically diverse cohort. The “high-risk” designation  
100 for inclusion referred to hazardous occupational exposure (e.g., healthcare workers) but also to advanced  
101 age or other sociodemographic characteristics known to increase risk of SARS-CoV-2 morbidity and  
102 mortality. Following written informed consent, participants provided demographic details to include social  
103 and lifestyle habits and relevant past medical history that would preclude them to more severe SARS-CoV-2  
104 infection-related outcomes. They also provided details regarding their past medical history to include  
105 conditions like hypertension, hypercholesterolemia, previous SARS-CoV-2 infection, diabetes, and  
106 COVID-19 vaccine manufacturer, lifestyle factors like alcohol or drug consumption, and other details such

107 as age, biological sex, educational level, employment status, marital status, race, ethnicity, and sexual  
108 orientation. Those who suffered from SARS-CoV-2 infection with a documented positive nucleic acid  
109 amplification test (NAAT+) prior to entry provided evidence details regarding their past SARS-CoV-2  
110 infection associated symptoms during the baseline visit to the study team.

111

112 At all regularly scheduled visits, participants prospectively answered symptom questionnaires to screen for  
113 new or recent SARS-CoV-2 infection, and blood samples were collected for serum and peripheral blood  
114 mononuclear cell (PBMC) processing. Plasma was stored at -80°C and PBMCs were cryopreserved in  
115 liquid N<sub>2</sub> (26). All participants agreed to sample banking for future research use (Fig 1).

116

117 **Fig 1. Overview of Experimental Methods.** Classification of intrinsic and extrinsic health factors were  
118 determined by participant responses gathered during baseline questionnaires. Blood samples were collected  
119 at regular intervals, followed by processing and ELISA-mediated antibody detection with discrete titers  
120 reported from 1:100 to 1:204800. Sample analysis was achieved through cross-sectional and longitudinal  
121 analyses. Created with BioRender.com

122

## 123 **SARS-CoV-2 ELISAs**

124 SARS-CoV-2 enzyme-linked immunosorbent assays (ELISAs) were performed according to a well  
125 described assay developed by the Icahn School of Medicine at Mount Sinai (27, 28). 96-well plates were  
126 collected at 4°C with wild-type Wuhan SARS-CoV-2 spike protein (2 mg/ml) solution and incubated  
127 overnight. Plates were blocked with 3% non-fat milk prepared in phosphate buffered saline with 0.1%  
128 Tween 20 (PBST) and incubated at room temperature for an hour. After blocking, serial dilutions of heat-  
129 inactivated serum samples were added to the plates and incubated for two hours at room temperature. Plates  
130 were washed in triplicate with 0.1 % PBST and 50 µl of a 1:3,000 dilution of goat anti-human  
131 immunoglobulin G-horseradish peroxidase (HRP) conjugated secondary antibody was added. After an hour

132 of incubation, 100  $\mu$ l *o*-phenylenediamine dihydrochloride (SIGMAFASTTM-OPD, *Sigma Aldrich*)  
133 solution was added to each well for 10 minutes. The reaction was stopped by the addition of 50  $\mu$ l of 3 M  
134 hydrochloric acid at each well. The optical density at 490 nm (OD490) was measured using a Synergy 4  
135 (BioTek) plate reader. The background value (OD490 = 0.15) allowed to report discrete antibody endpoint  
136 titers in the values of 1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400, 1:12800, 1:25600, 1:51200,  
137 1:102400, and 1:204800. The limit of detection was set at 1:100.

138

## 139 **Statistical analyses**

140 For all analyses, regardless of the statistical approach, Ab titers were  $\log_2$  transformed. Intrinsic and  
141 extrinsic factors (Table 1) were included in the cross-sectional and longitudinal analyses detailed below.

142 **Table 1. Observed Extrinsic and Intrinsic Health Factors Selected as Covariates.**

<b>Extrinsic Health Factors</b>	<b>Intrinsic Health Factors</b>
Alcohol consumption	Age
Cardiovascular disease	Biological sex
SARS-CoV-2 infection (prior to vaccination)	Educational level
COVID-19 vaccine manufacturer	Employment status
Diabetes	Marital status
Hypercholesterolemia	Race (White/Black/Asian/Other)
Hypertension	Ethnicity (Hispanic/Not Hispanic)
Recreational drug consumption (marijuana, cocaine, and/or hallucinogens)	Sexual orientation

143

## 144 **Cross-sectional analysis**

145 For the cross-sectional analysis, all respondents had participated in additional visits with associated Ab  
146 titers measured within 2 weeks [ $\pm$  5 days] following primary and booster vaccination. Cross-sectional  
147 analysis was conducted separately for post-vaccine timepoints following PV, BV1, and BV2. We included  
148 only those (n = 118) who had received their primary vaccination (i.e., two doses of Pfizer BNT162b2 or  
149 two doses of Moderna mRNA-1273) after their inclusion into the study and strictly within the two-dose

150 schedule recommended by the Centers for Disease Control and Prevention (CDC). This approach  
151 minimized potential discrepancies in vaccination effects based on administration time.

152

153 The underlying assumptions for parametric tests (e.g., tests for homogeneity of variance and normality)  
154 were conducted for Ab titers among IHF and EHF groups following each post-vaccination sub cohort of  
155 interest (i.e., PV1, BV1, and BV2) prior to conducting hypothesis testing. Differences in mean Ab were  
156 analyzed using parametric (one-way analysis of variance (ANOVA), Student's t-test) or non-parametric  
157 (Games-Howell, Welch's t-test) tests, based on Levene's test results. Lastly, Pearson's correlation was used  
158 to examine the correlation between age and peak Ab titer. All statistical analyses were conducted via  
159 Minitab (*Minitab*® 21.3.1) at a significance level of  $\alpha = 0.05$ , and tests for groups with sample sizes <2  
160 were excluded from analysis.

161

## 162 **Longitudinal analysis**

163 The selection of covariates of interest for the longitudinal analysis was informed by the aforementioned  
164 cross-sectional analysis conducted at post-primary vaccination timepoints. Preliminary analyses utilized a  
165 range of potential predictors to evaluate their association with the response variable,  $\log_2$  Ab titers over  
166 time. From this subset, only those predictors that exhibited a significant association  $\log_2$  Ab were carried  
167 forward as covariates of interest for the longitudinal analysis. This method ensured that the longitudinal  
168 model was informed by empirically significant predictors, thus increasing the potential explanatory power  
169 and relevance of the model to the observed data. Other proven covariates of interest (5), including COVID-  
170 19 vaccine manufacturer, were included during the model generation phase as well.

171

172 Following the above, linear mixed-effects models were constructed to investigate the growth curve of  $\log_2$   
173 antibody titers over time following primary vaccination (Dose 1 and 2), as well as booster vaccination (Dose  
174 3 and Dose 4) utilizing the *nlme* and *lme4* package in R Studio. The models were designed to incorporate

175 both fixed and random effects, with the fixed effects representing the average population response and the  
176 random effects capturing subject-specific deviations. The process of model generation was initiated by  
177 constructing a maximal model, where the time since vaccination – represented as a continuous variable –  
178 was incorporated as additional polynomial terms to account for potential non-linear growth patterns. This  
179 maximal model considered the most complex growth trajectory from the outset.

180

181 To account for the repeated measures structure of the data, various correlation structures including  
182 compound symmetry, first-order autoregressive, and general autoregressive were compared. Model  
183 comparison was performed using the Akaike Information Criterion (AIC) and the Bayesian Information  
184 Criterion (BIC), with the model yielding the lowest values being selected as the optimal model.

185

## 186 **Results**

### 187 **Cohort characteristics**

#### 188 **Extrinsic health factors - summary**

189 As seen in Table 1, among those enrolled (n = 228), the average age in the “CITY” cohort was  $48.6 \pm 16.56$   
190 years, with 66 (34.74%) participants classified as young, 84 (44.21%) as middle aged, and 40 (21.05%) as  
191 elderly (n = 190).

192 Table 2 displays a summary table for the cohort extrinsic health factors. At baseline, n = 180 (78.95%)  
193 participants self-reported as alcohol consumers and 47 (20.61%) did not (n = 227). There were 9 (3.96%)  
194 participants with a history of cardiovascular disease (CVD) , 216 (95.16%) with no history of CVD, and 2  
195 (0.88%) that were unsure (n = 227). Also, 9 (3.96%) participants were diabetic, while 215 (94.72%) were  
196 not, and 3 (1.32%) were unsure (n = 227). Moreover, 16 (7.08%) participants were recreational drug users  
197 and 210 (92.92%) were not (n = 226). Among the cohort, 39 (17.18%) of the participants had  
198 hypercholesterolemia, while 173 (76.21%) did not, and 14 (6.17%) were unsure (n = 227). Lastly, 37  
199 (16.30%) participants reported hypertension, 185 (81.50%) did not, and 5 (2.20%) were unsure (n = 227).



200

201 **Table 2. Cohort Extrinsic Health Factor Summary Table.**

<b>EXTRINSIC HEALTH FACTORS (N=228)</b>	
<b>Alcohol Consumption</b>	<b>N = 227</b>
No	47 (20.61%)
Yes	180 (78.95%)
<b>Cardiovascular Disease</b>	<b>N = 227</b>
No	216 (95.15%)
Yes	9 (3.96%)
Unsure	2 (0.88%)
<b>COVID-19</b>	<b>N = 228</b>
No	126 (55.26%)
Yes	99 (43.42%)
Unsure	3 (1.32%)
<b>COVID-19 Primary Vaccine Manufacturer</b>	<b>N = 163</b>
Johnson & Johnson Ad26.COV2.S	8 (4.91%)
Moderna mRNA-1273	58 (35.58%)
Pfizer BNT162b2	97 (59.51%)
<b>COVID-19 Booster I Manufacturer</b>	<b>N = 97</b>
Moderna mRNA-1273 – Full	17 (17.53%)
Moderna mRNA-1273 – Half	24 (24.74%)
Pfizer BNT162b2	56 (57.73%)
<b>COVID-19 Booster II Manufacturer</b>	<b>N = 32</b>
Moderna mRNA-1273 – Full	16 (50.00%)
Moderna mRNA-1273 – Half	1 (3.12%)
Pfizer BNT162b2	15 (46.88%)
<b>Diabetes</b>	<b>N = 227</b>
No	215 (94.71%)
Yes	9 (3.96%)
Unsure	3 (1.32%)
<b>Drug Use</b>	<b>N = 227</b>
No	210 (92.92%)
Yes	16 (7.08%)
<b>Hypercholesterolemia</b>	<b>N = 227</b>
No	173 (76.21%)
Yes	39 (17.18%)
Unsure	14 (6.17%)
<b>Hypertension</b>	<b>N = 227</b>
No	185 (81.50%)
Yes	37 (16.30%)
Unsure	5 (2.20%)

202

203 Ninety-nine (43.42%) participants indicated previous SARS-CoV-2 infection at entry, while 126 (55.26%)

204 did not, and 3 (1.32%) were unsure (n=228). Of the 163 participants in the cohort that received PV, 8

205 (4.91%) received Johnson & Johnson Ad26.COV2.S, 58 (35.58%) received Moderna mRNA-1273, and 97

206 (59.51%) received Pfizer BNT162b2. Of the 97 participants that received the first booster (BV1), 17  
207 (17.53%) received the full Moderna mRNA-1273 dose, 24 (24.74%) received the half-dose Moderna  
208 mRNA-1273, and 56 (57.73%) received Pfizer BNT162b2. Of those 32 participants that received a second  
209 booster (BV2), 16 (50%) received a full Moderna mRNA-1273 dose, 1 (3.12%) received the Moderna  
210 mRNA-1273 half dose, and 15 (46.88%) received a Pfizer BNT162b2 booster. No bivalent boosters were  
211 included in the analysis.

212

### 213 **Intrinsic health factors - summary**

214 Table 3 displays a summary table for the cohort intrinsic health factors. One hundred and thirty-seven  
215 (60.00%) participants were female and 91 (40.00%) were male (n = 228). Furthermore, it was reported that  
216 23 (10.10%) participants had an associate degree or a technical degree, 49 (21.49%) had a bachelor's  
217 degree, 12 (5.26%) had a high school diploma or equivalent, 3 (1.32%) had less than a high school diploma,  
218 111 (48.68%) had a master's degree or higher, and 29 (12.72%) had other educational levels (n = 227).

219

220 **Table 3. Cohort Intrinsic Health Factor Summary Table.**

<b>INTRINSIC HEALTH FACTORS (N = 228)</b>	
<b>Age</b>	<b>N = 190</b>
<40 – Young	66 (34.74%)
40-65 – Middle	84 (44.21%)
>65 – Elderly	40 (21.05%)
<b>Biological Sex</b>	<b>N = 228</b>
Female	137 (60.09%)
Male	91 (39.91%)
<b>Education Level</b>	<b>N = 227</b>
Associate degree or technical degree	23 (10.13%)
Bachelor's degree	49 (21.59%)
High school diploma or equivalent	12 (5.29%)
Master's degree or higher	111 (48.90%)
Other	29 (12.78%)
<b>Employment Status</b>	<b>N = 226</b>
Disabled	2 (0.88%)
Employed	188 (83.19%)
Retired	24 (10.62%)
Unemployed	12 (5.31%)
<b>Hispanic/Non-Hispanic</b>	<b>N = 228</b>

Hispanic	90 (39.47%)
Non-Hispanic	138 (60.53%)
<b>Marital Status</b>	<b>N = 228</b>
Divorced	19 (8.33%)
Domestic partnership	11 (4.82%)
Married	113 (49.56%)
Single	79 (34.65%)
Widowed	6 (2.64%)
<b>Race</b>	<b>N = 228</b>
Asian	12 (5.26%)
Black	12 (5.26%)
Other	21 (9.21%)
White	183 (80.27%)
<b>Sexual Orientation</b>	<b>N = 228</b>
Bisexual	3 (1.32%)
Gay	15 (6.58%)
Heterosexual	206 (90.34%)
Lesbian	3 (1.32%)
Other	1 (0.44%)

221

222 Additionally, 2 (0.87%) participants were disabled, 188 (82.46%) were employed, 24 (10.54%) were  
223 retired, and 12 (5.26%) were unemployed (n=226). Nineteen (8.33%) were divorced, 11 (4.82%)  
224 participated in a domestic partnership, 113 (49.57%) were married, 79 (34.65%) were single, and 6 (2.63%)  
225 were widowed (n = 228). In addition, 12 (5.26%) participants identified as Asian, 12 (5.26%) as African  
226 American, 183 (80.27%) as White, and 21 (9.21%) as part of another race (n = 228). Ninety (39.47%)  
227 participants identified as Hispanic, and 138 (60.53%) participants identified as non-Hispanic. Lastly, 3  
228 (1.32%) participants identified as bisexual, 15 (6.58%) as gay, 206 (90.35%) as heterosexual, 3 (1.32%) as  
229 lesbian, and 1 (0.43%) as another sexual orientation (n = 228).

230

## 231 **Primary vaccination**

232 Overall, 148 participants were included in the PV sub-cohort, with an average peak titer of  $13.29 \pm 1.67$   
233 following vaccination. Table 4 details all significant differences observed across extrinsic and intrinsic  
234 health factor covariates in the PV sub-cohort or that had significance in the BV1 and BV2 sub-cohorts.  
235 Other measures examined for the purpose of this analysis are documented in S1 Table.

236

237 **Table 4. Mean Log<sub>2</sub> Ab Titers in Primary Vaccination Sub-Cohort with Varying Extrinsic and**  
 238 **Intrinsic Health Factors.**

<b>PRIMARY VACCINATION</b>			
<i>EXTRINSIC HEALTH FACTORS</i>			
<b>COVID-19</b>	<b>N</b>	<b>Mean log<sub>2</sub> Ab (± SD)</b>	<b>p</b>
<i>Primary Vaccination (n = 148)</i>			
<i>No</i>	94 (63.15%)	12.62 (± 1.59)	<b>&lt;0.005 *</b>
<i>Yes</i>	54 (36.49%)	14.39 (± 1.15)	
<b>Drug Use</b>			
<i>Primary Vaccination (n = 148)</i>			
<i>No</i>	139 (93.92%)	13.20 (± 1.70)	<b>0.050 *</b>
<i>Yes</i>	9 (6.08%)	14.31 (± 0.70)	
<i>INTRINSIC HEALTH FACTORS</i>			
<b>Age</b>			
<i>Primary Vaccination (n = 149)</i>			
<i>&lt;40 – Young</i>	55 (36.91%)	13.57 (± 1.41)	<b>0.026 *</b>
<i>40-65 – Middle</i>	60 (40.27%)	13.36 (± 1.75)	
<i>&gt;65 – Elderly</i>	34 (22.82%)	12.61 (± 1.78)	
<b>Biological Sex</b>			
<i>Primary Vaccination (n = 149)</i>			
<i>Female</i>	86 (57.72%)	13.56 (± 1.46)	<b>0.015 *</b>
<i>Male</i>	63 (42.28%)	12.87 (± 1.86)	
<b>Employment Status</b>			
<i>Primary Vaccination (n = 148)</i>			
<i>Employed</i>	125 (84.46%)	13.36 (± 1.63)	<b>0.037 *</b>
<i>Retired</i>	17 (11.49%)	12.35 (± 1.96)	
<i>Unemployed</i>	6 (4.05%)	13.98 (± 0.82)	
<b>Hispanic/Non-Hispanic</b>			
<i>Primary Vaccination (n = 149)</i>			
<i>Hispanic</i>	57 (38.26%)	13.57 (± 1.77)	0.079
<i>Non-Hispanic</i>	92 (61.74%)	13.08 (± 1.58)	

239 Significant differences in peak Ab were observed between individuals with (14.39 ± 1.15) and  
 240 without (12.62 ± 1.59) a previous COVID-19 infection, drug users (14.31 ± 0.70) and non-users  
 241 (13.20 ± 1.70), elderly (12.61 ± 1.78) and young (13.57 ± 1.41) participants, employed (13.36 ±

242 1.63) and retired ( $12.35 \pm 1.96$ ) participants, and males ( $12.87 \pm 1.86$ ) and females ( $13.56 \pm 1.46$ )  
243 ( $T = -7.76; p < 0.005$ ,  $T = -1.95; p = 0.050$ ,  $F = 3.73; p = 0.026$ ,  $F = 3.37; p = 0.037$ ,  $T = 2.47$ ;  
244  $p = 0.015$ , respectively).

245 †: Levene's test found a statistically significant difference in the variances between COVID-19-  
246 vaccinated and unvaccinated individuals ( $F(1,147) = 4.92; p = 0.028$ ).

247 ‡: Levene's test found a statistically significant difference in the variances between female and  
248 male participants ( $F(1,148) = -4.68; p = 0.032$ ) after PV.

249 ††: Levene's test found a statistically significant difference in the variances between employed,  
250 unemployed, and retired participants ( $F(2,147) = 4.41; p = 0.015$ ) after BV1.

251

## 252 **Extrinsic health factors**

253 Five (3.42%) individuals included in the PV sub-cohort had CVD. while the remaining 141 (96.58%) did  
254 not. The mean  $\log_2$  Ab of participants with CVD ( $12.84 \pm 3.11$ ) and without CVD ( $13.29 \pm 1.59$ ) were not  
255 statistically different ( $T = 0.59; p = 0.555$ ). Four who received PV (2.72%) had diabetes and 143 (97.28%)  
256 did not. The mean  $\log_2$  Ab of participants with diabetes ( $12.89 \pm 2.87$ ) and participants without diabetes  
257 ( $13.31 \pm 1.61$ ) were not statistically different ( $T = 0.50; p = 0.619$ ). Twenty-seven (19.42%) had  
258 hypercholesterolemia while 112 (80.58%) did not. The mean  $\log_2$  Ab of participants with  
259 hypercholesterolemia ( $13.01 \pm 1.96$ ) and without hypercholesterolemia ( $13.31 \pm 1.60$ ) were not statistically  
260 different ( $T = 0.83; p = 0.405$ ). Furthermore, 22 (15.07%) had hypertension and 124 (84.93%) did not have  
261 hypertension. The variances of  $\log_2$  Ab between participants with hypertension and participants without  
262 hypertension were statistically different, ( $F(1,145) = 8.15; p = 0.005$ ) and indicated that individuals without  
263 hypertension had lower and more homogenous Ab response after PV. However, the mean  $\log_2$  Ab of  
264 participants with hypertension ( $12.69 \pm 2.36$ ) and participants without hypertension ( $13.34 \pm 1.50$ ) were  
265 not statistically different ( $T = 1.24; p = 0.225$ ).

266

267 Fifty-four (36.49%) of those that received PV reported prior SARS-CoV-2 infection at study entry and 94  
268 (63.51%) did not. The variances of  $\log_2$  Ab between participants with a history of COVID-19 and no history  
269 of COVID-19 were statistically different ( $F(1,147) = 4.92; p = 0.028$ ), as were the peak responses among  
270 participants with a COVID-19 history ( $14.39 \pm 1.15$ ) and no history of COVID-19 ( $12.62 \pm 1.59$ ) ( $T = -$   
271  $7.76; p < 0.005$ ). Furthermore, 149 participants received PV, where 54 (36.24%) received a Moderna  
272 vaccine and 95 received a Pfizer BNT162b2. The mean  $\log_2$  Ab of participants with the Moderna mRNA-  
273 1273 vaccine ( $13.50 \pm 1.71$ ) and the Pfizer BNT162b2 vaccine ( $13.14 \pm 1.64$ ) were not statistically  
274 different, as shown in Fig 2 ( $T = 1.26; p = 0.211$ ). Of the 148 participants who received PV, 119 (80.41%)  
275 were alcohol consumers and 29 (19.59%) were not alcohol consumers. The mean  $\log_2$  Ab of alcohol  
276 consumers ( $13.39 \pm 1.58$ ) and non-alcohol consumers ( $12.75 \pm 1.97$ ) were not significantly different ( $T = -$   
277  $1.87; p = 0.063$ ) after PV. Moreover, of the 148 participants that received PV, 9 (6.08%) were recreational  
278 drug users and 139 (93.92%) were not. The mean  $\log_2$  Ab of recreational drug users ( $14.31 \pm 0.70$ ) and  
279 non-users ( $13.20 \pm 1.70$ ) were statistically different ( $T = -1.95; p = 0.050$ ) after PV.

280

281 **Fig 2. Post-Primary Vaccination Mean  $\log_2$  Ab Across COVID Vaccine Groups.** There was no  
282 significant difference ( $T=1.26, p=0.211$ ) between mean  $\log_2$  Ab between participants who received  
283 Moderna mRNA-1273 ( $13.50 \pm 1.71$ ) or Pfizer BNT162b2 vaccines ( $13.14 \pm 1.64$ ) for their primary  
284 vaccination after 2 weeks of vaccination onset.

285

## 286 **Intrinsic health factors**

287 Of the 149 participants that received PV, 55 (36.91%) of them were young, 60 (40.27%) were middle aged,  
288 and 34 (22.82%) were elderly. The mean  $\log_2$  Ab of low age participants ( $13.57 \pm 1.41$ ; Tukey = A) was  
289 statistically different (Fig 3) than elderly participants ( $12.61 \pm 1.78$  ; Tukey = B), but not middle-aged  
290 participants ( $13.36 \pm 1.75$  ; Tukey = A , B) after PV ( $F = 3.73 ; p = 0.026$ ). Pearson correlation demonstrated  
291 a negative correlation between age and  $\log_2$  Ab after PV ( $r = -0.206; p = 0.012$ ). Additionally, 86 (57.72%)

292 participants were female and 63 (42.28%) were male. The variances of the  $\log_2$  Ab between female and  
293 male participants were significantly different ( $F(1,148) = 4.68$ ;  $p = 0.032$ ) after PV. Furthermore, male  
294 participants exhibited a lower ( $12.87 \pm 12.87$ ) was statistically lower ( $T = 2.47$ ;  $p = 0.015$ ) than that of  
295 female ( $13.56 \pm 1.46$ ) participants after PV (Fig 4).

296

297 **Fig 3. Post-Primary Vaccination Means  $\log_2$  Ab Across Age Groups.** The mean  $\log_2$  Ab of low age  
298 participants ( $13.57 \pm 1.41$ ; Tukey = A) was statistically different than elderly participants ( $12.61 \pm 1.78$  ;  
299 Tukey = B), but not middle-aged participants ( $13.36 \pm 1.75$  ; Tukey = A, B) after primary vaccination ( $F =$   
300  $3.73$  ;  $p = 0.026$ ).

301

302 **Fig 4. Post-Primary Vaccination Mean  $\log_2$  Ab Across Biological Sex Groups.** The mean  $\log_2$  Ab in  
303 male participants ( $12.87 \pm 12.87$ ) was statistically lower ( $T=2.47$ ,  $p=0.015$ ) than that of female ( $13.56 \pm$   
304  $1.46$ ) participants after primary vaccination

305

306 Furthermore, of the 149 participants that received PV, 12 (8.05%) reached an education level of an associate  
307 degree or technical degree, 30 (20.13%) held a bachelor's degree, 9 (6.04%) a high school diploma, 75  
308 (50.34%) a master's degree or higher, and 23 (15.44%) reported reaching an unlisted level. Peak titers were  
309 not associated with differences between any group ( $F = 1.87$ ) ; ( $p = 0.120$ ), including those with an associate  
310 degree or technical degree ( $13.56 \pm 1.44$  ; Tukey = A), a bachelor's degree ( $13.68 \pm 1.69$  ; Tukey = A), a  
311 high school diploma ( $13.98 \pm 1.58$  ; Tukey = A), a master's degree or higher ( $13.16 \pm 1.64$  ; Tukey = A),  
312 and other educational levels ( $12.64 \pm 1.76$  ; Tukey = A). One-hundred and twenty-five (84.46%) were  
313 employed, 17 (11.49%) were retired, and 6 (4.05%) were unemployed. The mean  $\log_2$  Ab of employed  
314 ( $13.36 \pm 1.63$ , Tukey = A), retired ( $12.35 \pm 1.96$ ; Tukey = A), and unemployed ( $13.98 \pm 0.82$ , Tukey = A)  
315 participants were statistically different ( $F = 3.37$  ;  $p = 0.037$ ) after PV, though the authors speculate that  
316 this finding is due to a strong correlation between age and the retired group.

317

318 Twelve (8.05%) participants were divorced, 7 (4.70%) participated in a domestic partnership, 81 (54.36%)  
319 were married, 47 (31.54%) were single, and 2 (1.35%) were widowed. The post PV Ab between divorced  
320 ( $13.81 \pm 1.24$ , *Tukey* = A), domestic partnership ( $13.07 \pm 1.51$ , *Tukey* = A), married ( $13.04 \pm 1.82$ , *Tukey*  
321 = A), and single ( $13.54 \pm 1.49$ , *Tukey* = A) participants were not statistically different ( $F = 1.36$ ;  $p = 0.257$ )  
322 after PV. Only 2 (1.34%) identified as bisexual, 10 (6.71%) identified as gay, 134 (89.94%) identified as  
323 heterosexual, 2 identified as lesbian (1.34%), and 1 (0.67%) identified as another sexual orientation.  
324 Furthermore, the mean  $\log_2$  Ab between gay ( $13.34 \pm 0.45$ ) and heterosexual ( $13.24 \pm 0.15$ ) participants  
325 were not significantly different ( $T = 0.19$ ;  $p = 0.853$ ) after PV.

326  
327 Also, of the 149 participants that received PV, 9 (6.04%) were Asian, 6 (4.03%) were African American,  
328 14 (9.40%) identified under another race, and 120 (80.54%) were White, though the mean peak response  
329 ( $13.09 \pm 1.88$ , *Tukey* = A;  $13.98 \pm 0.82$ , *Tukey* = A;  $13.43 \pm 1.37$ , *Tukey* = A;  $13.23 \pm 1.72$ , *Tukey* = A;  
330 respectively) were not statistically different ( $F = 0.46$  ;  $p = 0.712$ ) after PV. Moreover 57 (38.26%)  
331 participants identified as Hispanic, and 92 (61.74%) identified as non-Hispanic. The mean  $\log_2$  Ab between  
332 Hispanic ( $13.57 \pm 1.77$ ) and non-Hispanic ( $13.08 \pm 1.58$ ) participants were not statistically different ( $T =$   
333  $1.77$ ;  $p = 0.079$ ) after PV.

334

### 335 **Longitudinal analysis following primary vaccination**

336 A linear mixed-effects model (Fig 5) was employed to investigate the fixed effects of days since full  
337 vaccination (including linear, quadratic, and cubic time), COVID-19 vaccine manufacturer, COVID-19  
338 status, and biological sex on the log-transformed titer levels (antibody), while accounting for random effects  
339 associated with each study participant. The fixed effects of linear, cubic, and quadratic time revealed that  
340 days since full vaccination (i.e., >14 days following the 2<sup>nd</sup> dose) and its second and third powers were  
341 negatively associated with  $\log_2$  antibody titers (*estimate* =  $-4.653e^{-03}$ ;  $F(1,524) = 96.889$ ;  $p = <0.001$ ,  
342 *estimate* =  $-2.208e^{-04}$ ;  $F(1,524) = 118.393$ ;  $p <0.001$ , and *estimate* =  $9.467e^{-07}$ ;  $F(1,24) = 44.654$ ;  $p <$



343 0.001, respectively). Participants who had been vaccinated with Pfizer BNT162b2 had a lower antibody  
344 response over time compared to those who received the Moderna mRNA-1273 vaccine ( $estimate = -9884e^{-}$   
345  $01; F(1,108) = 36.900; p < 0.001$ ).

346

347 **Fig 5. Linear Mixed-Effects Model for Investigation of Fixed Effects of Days Since Full Vaccination,**  
348 **Primary Covid-19 Vaccine Manufacturer, Covid-19 Status, And Biological Sex.** Moderna mRNA-1273  
349 recipients exhibited higher peak titers as well as more durable antibody responses when compared to Pfizer  
350 BNT162b2, as did study participants who were previously COVID-19 positive prior to vaccine recipient.  
351 Male participants, on average, demonstrated lower Ab responses when compared to female participants.

352

353 Additionally, COVID-19 positive participants had higher antibody levels compared to COVID-19 negative  
354 individuals ( $estimate = 1.464; F(1,108) = 64.917; p < 0.001$ ), consistent with well-described trends for  
355 hybrid immunity (29). The analysis also suggested a difference in antibody levels based on biological sex,  
356 with males having lower levels compared to females ( $estimate = -3.759e^{01}; F(1,108) = 4.856; p = 0.030$ ).  
357 No other variable was found to significantly influence  $\log_2$  antibody titers over time (S2 Table).

358

## 359 **Booster vaccine I**

360 Following Booster Vaccine I (BV1), 148 participants averaged a mean peak titer of  $17.74 \pm 1.14$ . Table 5  
361 details significant differences observed across all extrinsic and intrinsic health factors in the BV1 sub-cohort  
362 or that were noted to be significant in the PV and BV2 sub-cohorts. Other measures are documented in S3  
363 Table.

364

365 **Table 5. Mean  $\log_2$  Ab titers in first booster vaccination sub-cohort with varying extrinsic and**  
366 **intrinsic health factors.**

---

### BOOSTER VACCINATION I

#### EXTRINSIC HEALTH FACTORS – BOOSTER VACCINATION I

---

<b>COVID-19</b>	N	Mean log <sub>2</sub> Ab (± SD)	<i>p</i>
<b>Booster Vaccination I (n = 98)</b>			
No	68 (69.39%)	14.70 (± 1.20)	0.649
Yes	30 (30.61%)	14.81 (± 1.02)	
<b>Drug Use</b>			
<b>Booster Vaccination I (n=97)</b>			
No	93 (95.88%)	14.74 (± 1.15)	0.794
Yes	4 (4.12%)	14.89 (± 0.96)	
<b>INTRINSIC HEALTH FACTORS – VACCINATED PARTICIPANTS</b>			
<b>Age</b>			
<b>Booster Vaccination I (n=98)</b>			
<40 – Young	24 (24.49%)	15.06 (± 0.97)	0.277
40-65 – Middle	43 (43.88%)	14.62 (± 0.96)	
>65 – Elderly	31 (31.63%)	14.64 (± 1.44)	
<b>Biological Sex</b>			
<b>Booster Vaccination I (n=98)</b>			
Female	<b>50 (51.02%)</b>	<b>14.96 (± 1.22)</b>	<b>0.043 *</b>
Male	<b>48 (48.98%)</b>	<b>14.50 (± 1.01)</b>	
<b>Employment Status</b>			
<b>Booster Vaccination I (n=97)</b>			
Employed	78 (80.41%)	14.82 (± 0.94)	0.541
Retired	14 (14.43%)	14.29 (± 1.91)	
Unemployed	5 (5.16%)	15.04 (± 0.89)	
<b>Hispanic/Non-Hispanic</b>			
<b>Booster Vaccination I (n=98)</b>			
Hispanic	34 (34.69%)	14.97 (± 0.98)	0.144
Non-Hispanic	64 (65.31%)	14.61 (± 1.21)	

367 Significant differences in peak Ab were observed between males (14.50 ± 1.01) and females

368 (14.96 ± 1.22) following BV1 ( $T = -2.05$ ;  $p = 0.043$ ).

369

### 370 **Extrinsic health factors**

371 Of the 95 participants that received BV1, 3 (3.16%) had CVD and 92 (96.84%) did not have CVD.

372 Additionally, the mean log<sub>2</sub> Ab of participants with CVD (14.64 ± 1.00) and participants without CVD

373 (14.75 ± 1.15) did not significantly vary ( $T = 0.16$ ;  $p = 0.872$ ) after BV1. Three (3.12%) had diabetes and

374 93 (96.88%) did not, but diabetic (13.98 ± 1.53) and non-diabetic (14.77 ± 1.14) participants did not have

375 observable differences ( $T = 1.19$ ;  $p = 0.239$ ) in peak titers. Of the 89 participants that received BV1, 23  
376 (25.84%) had hypercholesterolemia and 66 (74.16%) did not. Eighteen (18.95%) participants had  
377 hypertension and 77 (81.05%) did not. Among participants with hypercholesterolemia ( $14.73 \pm 0.95$ ) or  
378 without ( $14.81 \pm 1.25$ ), and hypertension ( $14.81 \pm 0.22$ ) or without ( $14.75 \pm 1.12$ ), we did not observe  
379 differences in peak BV1 response ( $T = 0.28$ ;  $p = 0.781$ ,  $T = -0.21$ ;  $p = 0.836$ ).

380  
381 Thirty (30.61%) participants who received BV1 were previously infected with SARS-CoV-2 and 68  
382 (69.39%) were not. Furthermore, the mean  $\log_2$  Ab of participants with a COVID-19 history ( $14.81 \pm 1.02$ )  
383 and no history ( $14.70 \pm 1.20$ ) were not statistically different ( $T = -0.46$ ;  $p = 0.649$ ) after BV1. In the BV1  
384 sub-cohort, 17 (17.52%) received a full-dose Moderna mRNA-1273 vaccine, while 24 (24.74%) received  
385 a half-dose Moderna mRNA-1273 vaccine, and 56 (56.74%) received a Pfizer BNT162b2 vaccine, but the  
386 mean  $\log_2$  Ab in participants with full-dose Moderna mRNA-1273 ( $14.82 \pm 1.55$  ; *Tukey* = A), half-dose  
387 Moderna mRNA-1273 ( $15.14 \pm 0.78$  ; *Tukey* = A), and Pfizer BNT162b2 ( $14.54 \pm 1.10$   $\log_2$  Ab ; *Tukey* =  
388 A) did not have significantly distinct peak responses ( $F = 2.51$  ;  $p = 0.087$ ).

389  
390 Interestingly, the Pfizer BNT162b2 BV1 group exhibited a very homogeneous peak response following  
391 vaccination ( $14.54$ ;  $SE = 0.02$ ) while ultimately it was not statistically different from the other groups. Of  
392 the 97 participants that received BV1, 74 (76.29%) were alcohol consumers and 23 (23.71%) were not. The  
393 peak response of alcohol consumers ( $14.85 \pm 1.01$ ) and non-consumers ( $14.43 \pm 1.48$ ) were not significantly  
394 different ( $T = -1.55$ ;  $p = 0.124$ ). Four (4.12%) participants were recreational drug users and 93 (95.88%)  
395 were not, and the peak response was not significantly different ( $T = -0.26$ ;  $p = 0.794$ ) between drug users  
396 ( $14.89 \pm 0.96$ ) and non-users ( $14.74 \pm 1.15$ ).

397

398 **Intrinsic health factors**

399 Twenty-four (24.49%) young participants were in the BV1 sub-cohort, while 43 (43.88%) were of middle  
400 age, and 34 (34.69%) were elderly. The peak response among different age groups was not significantly  
401 different ( $F = 1.30$ ;  $p = 0.277$ ), including young ( $15.06 \pm 0.97$ ;  $Tukey = A$ ), middle-aged ( $14.62 \pm 0.96$ ,  
402  $Tukey = A$ ), and elderly participants ( $14.46 \pm 1.44$ ;  $Tukey = A$ ). Of the 98 participants that received BV1,  
403 50 (51.02%) were female and 48 (49.98%) were male, and a significantly lower peak response ( $T = -2.05$ ;  
404  $p = 0.043$ ) was observed in males ( $14.50 \pm 1.01$ ) in comparison to females ( $14.96 \pm 1.22$ ).

405  
406 Of the 98 participants that received BV1, 10 (10.20%) obtained an associate degree or technical degree, 21  
407 (21.43%) a bachelor's degree, 2 (2.04%) a high school diploma, 48 (48.98%) a master's degree or higher,  
408 and 17 (17.35%) reported an unlisted level. The mean  $\log_2$  Ab between participants with an associate degree  
409 or technical degree ( $14.84 \pm 1.62$ ;  $Tukey = A$ ), a bachelor's degree ( $14.64 \pm 1.38$ ;  $Tukey = A$ ), a master's  
410 degree or higher ( $14.81 \pm 0.91$ ;  $Tukey = A$ ), and other educational levels ( $14.64 \pm 1.23$ ;  $Tukey = A$ ) were  
411 not statistically different ( $F = 0.17$ ;  $p = 0.916$ ). Seventy-eight participants (80.41%) were employed, 14  
412 (14.43%) were retired, and 5 (5.16%) were unemployed. We observed that the variances of  $\log_2$  Ab between  
413 employed, retired and unemployed participants were statistically different ( $F (2,147) = 4.41$ ;  $p = 0.015$ )  
414 after BV1, though the peak responses were not significantly different ( $F = 0.66$ ;  $p = 0.541$ ) between these  
415 groups ( $14.82 \pm 0.94$ ,  $Games-Howell = A$ ;  $14.29 \pm 1.91$ ,  $Games-Howell = A$ ;  $15.04 \pm 0.89$ ;  $Games-Howell$   
416  $= A$ ; respectively).

417  
418 In the BV1 sub-cohort, 8 (8.16%) participants were divorced, 4 (4.08%) participated in a domestic  
419 partnership, 61 (62.24%) were married, 22 (22.45%) were single, and 3 (3.07%) were widowed. The mean  
420  $\log_2$  Ab between divorced ( $15.02 \pm 1.06$ ;  $Tukey = A$ ), domestic partnership ( $14.39 \pm 0.96$ ;  $Tukey = A$ ),  
421 married ( $14.68 \pm 1.22$ ;  $Tukey = A$ ), single ( $14.83 \pm 1.01$ ;  $Tukey = A$ ), and widowed ( $14.98 \pm 1.16$ ;  $Tukey =$   
422  $A$ ) participants were not statistically different ( $F = 0.31$ ;  $p = 0.869$ ) after BV1. One (1.02%) identified as  
423 bisexual, 6 (6.12%) identified as gay, 90 (91.84%) identified as heterosexual, and 1 identified as lesbian

424 (1.02%), but the mean  $\log_2$  Ab between gay ( $14.31 \pm 0.82$ ) and heterosexual ( $14.74 \pm 1.15$ ) participants  
425 were not significantly different ( $T = -0.90$ ;  $p=0.368$ ) following BV1.

426

427 Finally, of the 98 participants that received BV1 8 (8.16%) were Asian, 3 (3.06%) were African American,  
428 5 (5.11%) identified under another race, and 82 (83.67%) were White. The peak responses between  
429 participants among different races were not statistically different ( $F = 0.41$ ;  $p = 0.747$ ), including Asian  
430 ( $14.77 \pm 0.84$  ; *Tukey* = A), African American ( $15.32 \pm 0.58$ ; *Tukey* = A), Other ( $15.04 \pm 0.55$  ; *Tukey* = A),  
431 and White ( $14.69 \pm 1.21$ ; *Tukey* = A). Of the 98 participants that received BV1, 34 (34.69%) identified as  
432 Hispanic, and 64 (65.31%) identified as non-Hispanic. The mean  $\log_2$  Ab between Hispanic ( $14.97 \pm 0.98$ )  
433 and non-Hispanic ( $14.61 \pm 1.21$ ) participants were not statistically different ( $T = 1.47$ ;  $p = 0.144$ ) after BV1.

434

### 435 **Longitudinal analysis following booster vaccination I**

436 Linear mixed effects models were generated to examine the effect of IHFs and EHF on  $\log_2$  antibody titers  
437 over time following BV1 (Fig 6). Overall, we found that the quadratic (*estimate* =  $-6.657e-04$ ;  $F(1, 72) =$   
438  $4.007$ ;  $p = 0.049$ ) and cubic (*estimate* =  $1.827e-06$ ;  $F(1, 72) = 10.142$ ;  $p = 0.002$ ) terms for days elapsed  
439 since the first booster were observed to be a significant predictor of  $\log_2$  antibody titers over time,  
440 elucidating a non-linear decay pattern following BV1. Curiously, this analysis also revealed that drug use  
441 positively impacted  $\log_2$  antibody titers, (*estimate* =  $2.527e+00$ ;  $F(1, 24) = 8.917$ ;  $p = .006$ ). Following  
442 post-hoc testing, booster type (i.e., Pfizer BNT162b2 vs. Moderna mRNA-1273 (full dose) vs. Moderna  
443 mRNA-1273 (half dose) was found to significantly affect the trajectory of  $\log_2$  antibody titers, (*estimate* =  
444  $3.997416e-01$ ;  $F(2, 24) = 4.755$ ;  $p = .018$ ), with those who received a half-dose of the Moderna mRNA-  
445 1273 booster displaying increased  $\log_2$  antibody titers boasting significantly higher titers than who received  
446 the Pfizer BNT162b2 booster.

447

448 **Fig 6. Linear mixed-effects model for investigation of IHFs and EHF's on log<sub>2</sub> antibody titers over**  
 449 **time following BV1.** The quadratic and cubic terms for days indicate a nonlinear decay of titers over  
 450 time. Additionally, the model indicated that drug use and vaccination with the half-dose Moderna mRNA-  
 451 1273 vaccine positively impacted titers. Other factors did not contribute significantly to titers over time.  
 452  
 453 Notably, factors such as ethnicity, gender, age at entry, race, and the linear term for the number of days  
 454 since the first boost did not significantly contribute to the variation in log<sub>2</sub> antibody titers, all  $p > .05$  (S4  
 455 Table).

456

## 457 **Booster vaccine II**

458 In the cohort, 24 participants received BV2 and averaged  $15.06 \pm 1.61$  Ab following vaccination. Table 6 details the  
 459 extrinsic and intrinsic health factors that observed a significant difference within groups in the BV2 cohort or that had  
 460 significance in the PV and BV1 sub-cohorts. Other measures are documented in S5 Table.

461

462 **Table 6. Mean log<sub>2</sub> Ab titers in second booster vaccination sub-cohort with varying extrinsic and**  
 463 **intrinsic health factors.**

<b>BOOSTER VACCINATION II</b>			
<i>EXTRINSIC HEALTH FACTORS</i>			
<i>COVID-19</i>	N	Mean log <sub>2</sub> Ab ( $\pm$ SD)	<i>p</i>
<i>Booster Vaccination II (n = 24)</i>			
<i>No</i>	21 (87.50%)	15.07 ( $\pm$ 1.69)	0.908
<i>Yes</i>	3 (12.50%)	14.98 ( $\pm$ 1.16)	
<i>Drug Use</i>			
<i>Booster Vaccination II (n=23)</i>			
<i>No</i>	21 (91.30%)	15.03 ( $\pm$ 1.65)	--
<i>Yes</i>	2 (8.70%)	16.14 ( $\pm$ 0.71)	
<i>INTRINSIC HEALTH FACTORS</i>			
<i>Age</i>			
<i>Booster Vaccination II (n = 24)</i>			
<i>&lt;40 – Young</i>	--	--	0.573

<i>40-65 – Middle</i>	7 (29.17%)	15.36 (± 1.50)	
<i>&gt;65 – Elderly</i>	17 (70.83%)	14.94 (± 1.69)	
<b>Biological Sex</b>			
<i>Booster Vaccination II (n=24)</i>			
Female	10 (41.67%)	15.04 (± 1.78)	0.967
Male	14 (58.33%)	15.07 (± 0.42)	
<b>Employment Status</b>			
<i>Booster Vaccination II (n=24)</i>			
<i>Employed</i>	14 (58.33%)	15.29 (± 1.50)	0.556
<i>Retired</i>	9 (37.50%)	14.87 (± 1.86)	
<i>Unemployed</i>	1 (4.17%)	--	
<b>Hispanic/Non-Hispanic</b>			
<i>Booster Vaccination II (n=24)</i>			
<i>Hispanic</i>	4 (16.67%)	16.64 (± 0.82)	<b>0.028 *</b>
<i>Non-Hispanic</i>	20 (83.33%)	14.74 (± 1.55)	

464 There was a significant difference in peak Ab between Hispanic (16.64 ± 0.82) and non-Hispanic  
 465 (14.74 ± 1.55) participants following BV2 ( $T = 2.35$ ;  $p = 0.028$ ).

466

## 467 Extrinsic health factors

468 In the BV2 sub-cohort 2 (9.09%) had CVD and 20 (90.91%) did not have CVD, 2 (8.70%) had diabetes  
 469 and 21 (91.30%) did not have diabetes, and 10 (47.62%) had hypercholesterolemia and 11 (52.38%) did  
 470 not have hypercholesterolemia. The peak response of participants with hypercholesterolemia (15.54 ± 0.99)  
 471 and without (14.92 ± 2.01) were not statistically different ( $T = -0.89$ ;  $p = 0.383$ ) after BV2. Five (21.74%)  
 472 had hypertension and 18 (78.26%) did not, but the peak responses between those with hypertension (15.84  
 473 ± 0.37) and without (14.92 ± 1.74) were not statistically different ( $T = -1.13$ ;  $p = 0.270$ ).

474

475 Three (12.50%) participants from the BV2 sub-cohort were infected with SARS-CoV-2 prior to enrollment  
 476 and 21 (87.50%) were not. The mean log<sub>2</sub> Ab of participants with prior SARS-CoV-2 infection (14.98 ±  
 477 1.16) and no prior infection (15.07 ± 1.69) were not statistically significant ( $T = 0.13$ ;  $p = 0.908$ ). Thirteen

478 (54.17%) received a full-dose Moderna mRNA-1273 vaccine, while 11 (45.83%) received a Pfizer  
479 BNT162b2 vaccine, but the peak responses between Moderna mRNA-1273 ( $15.41 \pm 1.74$ ) and Pfizer  
480 BNT162b2-vaccinated ( $14.64 \pm 1.41$ ) participants were not significantly different ( $T = 1.17$ ;  $p = 0.253$ ). Of  
481 the 23 participants that received BV2, 17 (73.91%) were alcohol consumers and 6 (26.09%) were not. The  
482 mean  $\log_2$  Ab of alcohol consumers ( $14.94 \pm 1.21$ ) and non-alcohol consumers ( $15.64 \pm 2.53$ ) were not  
483 significantly different ( $T = 0.91$ ;  $p = 0.371$ ) after BV2. Two (8.70%) participants were drug users and 21  
484 (91.30%) were not.

485

### 486 **Intrinsic health factors**

487 Of the 24 participants that received BV2, 7 (29.17%) were middle aged and 17 (70.83%) were elderly. The  
488 peak response of middle-aged participants ( $15.36 \pm 1.50$ ) and elderly participants ( $14.96 \pm 1.69$ ) was not  
489 significantly different ( $T = -0.57$ ;  $p = 0.573$ ). Ten (41.67%) participants were female and 14 (58.33%) were  
490 male, and the peak response in male ( $15.07 \pm 0.42$ ) and female ( $15.04 \pm 1.78$ ) participants was not  
491 statistically different ( $T = -0.04$ ;  $p = 0.967$ ) after BV2.

492

493 Two (8.33%) participants had an associate degree or technical degree, 5 (20.83%) had a bachelor's degree,  
494 13 (54.17%) had a master's degree or higher, and 4 (16.67%) had an unlisted degree. The peak responses  
495 among participants in this group were not statistically different ( $F = 0.64$ ,  $p = 0.539$ ), including those with  
496 a bachelor's degree ( $14.44 \pm 2.39$ ;  $Tukey = A$ ), a master's degree or higher ( $14.03 \pm 1.26$ ;  $Tukey = A$ ), and  
497 other educational levels ( $15.64 \pm 1.41$ ;  $Tukey=A$ ). Of the 24 participants that received BV2, 14 (58.33%)  
498 were employed, 9 (37.50%) were retired, and 1 (4.17%) was unemployed. The Ab of employed ( $15.29 \pm$   
499  $1.50$ ) and retired ( $14.87 \pm 1.86$ ) participants were not statistically different ( $T = 0.60$ ;  $p = 0.556$ ) after BV2.

500

501 In the BV2 cohort, 3 (12.50%) participants were divorced, 1 (4.17%) participated in a domestic partnership,  
502 16 (66.67%) were married, 2 (8.33%) were single, and 2 (8.33%) were widowed. The mean  $\log_2$  Ab between



503 divorced ( $15.98 \pm 0.58$ ) and married ( $14.77 \pm 1.75$ ) participants were not statistically different ( $T = 1.61$ ;  $p$   
504  $= 0.261$ ). Two (8.33%) identified as gay and 22 (91.67%) identified as heterosexual.

505  
506 Four (16.67%) identified as Hispanic, and 20 (83.33%) identified as non-Hispanic. The peak response  
507 between Hispanic ( $16.64 \pm 0.82$ ) and non-Hispanic ( $14.74 \pm 1.55$ ) participants were statistically different  
508 ( $T = 2.35$ ;  $p = 0.028$ ) after BV2. Of the 24 participants that received BV2, 2 (8.33%) were Asian, 2 (8.33%)  
509 were African American, 2 (8.33%) identified under another race, and 18 (75.01%) were White.

510

## 511 **Longitudinal analysis following booster vaccination II**

512 Lastly, linear mixed effects models were used to generate a growth curve of the  $\log_2$  Ab response following  
513 BV2. Again, the quadratic term for the number of days since the 2<sup>nd</sup> booster emerged as a significant  
514 predictor of  $\log_2$  antibody titers, ( $estimate = -6.628 \times 10^{-5}$ ;  $F(1, 104) = 7.916$ ;  $p = .006$ ), suggestive of a non-  
515 linear decay pattern following vaccination. No other covariate of interest was found to significantly affect  
516 the trajectory of Ab over time, including linear or cubic time, gender, booster type, or drug use (S6 Table).  
517 Overall, these results suggest that a 4<sup>th</sup> dose of an mRNA COVID-19 vaccine provide an additive effect on  
518 the immune response, dampening the role of underlying IHF and EHF that may influence the post-vaccine  
519 immune response.

520

## 521 **Discussion**

522 In this work, we sought to evaluate the effects of intrinsic and extrinsic health factors on the peak antibody  
523 response as well as characterize antibody trajectory over time following COVID-19 mRNA primary  
524 vaccination and booster vaccination. Through cross-sectional analysis, we found that EHF influenced Ab  
525 production after primary vaccination. Participants that reported recreational drug use, including marijuana,  
526 cocaine, and amphetamines had marginally higher  $\log_2$  Ab compared to non-users after PV, but not BV1 or

527 BV2. Previous work has shown that recreational drug use is immunomodulatory, increasing the  
528 susceptibility to infectious diseases and microbes while impairing antibody production following  
529 vaccination (30-33). Our findings support the opposite, though this warrants further investigation given the  
530 small sample size of drug users in our cohort. This was further substantiated in linear mixed-effects models,  
531 which demonstrated that participants with reported drug use had higher titers over time only after BV1.

532  
533 Our cross-sectional analyses were inherently limited in their ability to control for all other variables that  
534 may influence humoral responses and were utilized in the context of this work to capture only the peak  
535 antibody response. Further, unlike mixed effects models, a cross-sectional approach does not permit the  
536 assessment of the impact of individual covariates while controlling for the effect of time elapsed since  
537 vaccination. We also found that individuals without hypertension had a lower and more homogeneous Ab  
538 response following PV, but not BV1 or BV2, which may be attributed to previously reported changes in T  
539 cell immunometabolism (i.e., aberrant T cell activation, differentiation, and proliferation) (34-38). Studies  
540 evaluating the effect of hypertension on antibody titers have provided variable results, with some supporting  
541 hypertension as a factor driving vaccine immunogenicity (37, 38), and others refuting it (39). We also  
542 observed significantly higher mean peak  $\log_2$  Ab in participants with previous SARS-CoV-2 infection  
543 compared to those without a history after only PV, consistent with previous findings (5, 40, 41). Lastly, no  
544 significant difference in the peak  $\log_2$  Ab was found between participants that received Moderna mRNA-  
545 1273 and Pfizer BNT162b2 vaccines after vaccination, although this was not the case over time.

546  
547 Young (low age) individuals had higher peak Ab compared to elderly participants, but not middle-aged  
548 participants only after PV, which may be attributed to age-related defects in lymphocytes like mature  
549 lymphocyte senescence or decreased production and proliferation of lymphocytes and their associated  
550 biomarkers (42-46). Furthermore, we observed significantly lower Ab in retired participants following PV,  
551 which likely corresponds to the advanced age of those participants. Also, we found that non-Hispanic  
552 participants had lower Ab than Hispanic after BV2, but our sample size is limited and therefore may be

553 limited in generalizability. Lastly, we found that females had significantly higher Ab following PV and  
554 BV1, but not BV2. Differences in immune responses based on biological sex may be linked to phylogenetic  
555 preservation and subsequent reproductive success associated with more robust humoral immune reaction  
556 in females (47). Accordingly, the decreased peak Ab responses we observed in males is supported by  
557 previously documented sex-related humoral and cellular-mediated differences (40, 47-49).

558  
559 The overall findings from the cross-sectional approach indicate, at least in part, the role of EHF and IHF  
560 in generating differential humoral immune response following COVID-19 vaccination. Notably, these  
561 analyses did not control for other variables, which increases the likelihood of introducing confounding  
562 factors in the analysis. Thus, cross-sectional analyses should be considered useful in identifying differences  
563 in immune response following vaccination but are perhaps limited in evaluating how these change over  
564 time. Additionally, controlling for other factors can help determine more robust relationships between Ab  
565 and IHF/EHF. Because the immune system follows a dynamic response following activation both through  
566 time and due to inter-individual differences, adopting models that account for this and can control for these  
567 differences may be used to corroborate cross-sectional analysis. Thus, distinct linear mixed-effects models  
568 were used to investigate the factors influencing the log-transformed titer levels following primary and  
569 booster vaccination. The number of days elapsed since primary vaccination was negatively associated with  
570 antibody titer magnitude, suggesting that as time passes since full vaccination, the titer levels decrease. This  
571 time-dependent decay of antibodies was observed to have significant nonlinear components, particularly  
572 following BV1 and BV2.

573  
574 We also found that COVID-19 positive individuals had higher antibody levels following primary  
575 vaccination compared to COVID-19 negative individuals, and male participants had lower antibody titers  
576 compared to females. The type of vaccine received also affected antibody magnitude and durability; those  
577 who received the Pfizer BNT162b2 vaccine had lower titers than those who were given the Moderna  
578 mRNA-1273 vaccine. Differential antibody production between Moderna mRNA-1273 and Pfizer

579 BNT162b2 vaccines observed in our cohort are consistent with previous findings, which could be due to  
580 varied anti-spike activity generated by each vaccine type (50, 51). We also observed that Moderna mRNA-  
581 1273 half-dose recipients had higher post-booster Ab compared to those who received Pfizer BNT162b2  
582 vaccination over time, but this effect was not observed following BV2. Interestingly, post-BV2 Ab were  
583 not significantly affected by any predictive factors. This lack of predictors, including vaccine manufacturer,  
584 suggest a more robust and homogeneous humoral immune response following BV2.

585

## 586 **Conclusions**

587 Overall, this study aimed to examine the effects of intrinsic and extrinsic health factors on Ab following  
588 vaccination and through time using cross-sectional and longitudinal models. Differences in antibody titers  
589 among the cohort were observed after primary vaccination for individuals with a history of drug use, prior  
590 SARS-CoV-2 infection, hypertension, age, and biological sex. Differential titer production was also  
591 observed across females following BV1 and Hispanic participants following BV2. Linear-mixed effects  
592 models used in this study aimed to control for random and fixed effects like population responses and  
593 individual Ab variations over time and revealed trends in the decline of Ab over time following full  
594 vaccination, as well as effects by COVID-19 vaccine manufacturer, prior SARS-CoV-2 infection, and  
595 biological sex. Drug users and half-dose Moderna mRNA-1273 recipients had higher peak antibody titers  
596 over time following the first booster, while no predictive factors significantly affected post-second booster  
597 antibody responses. The absence of predictive factors for second booster immunogenicity suggests a more  
598 robust and consistent immune response after the second booster vaccine administration.

599

600

## 601 **Conflict of Interest**

602 Florian Krammer has been consulting for Curevac, Seqirus and Merck and is currently consulting for Pfizer,  
603 Third Rock Ventures, Avimex and GSK. He is named on several patent regarding influenza virus and  
604 SARS-CoV-2 virus vaccines, influenza virus therapeutics and SARS-CoV-2 serological tests. Some of  
605 these technologies have been licensed to commercial entities and Dr. Krammer is receiving royalties from  
606 these entities. Dr. Krammer is also an advisory board member of Castlevax, a spin-off company formed by  
607 the Icahn School of Medicine at Mount Sinai to develop SARS-CoV-2 vaccines. The Krammer laboratory  
608 has received funding for research projects from Pfizer, GSK and Dynavax and three of Dr. Krammer's  
609 mentees have recently joined Moderna. All other authors declare that they have no known competing  
610 financial interests or personal relationships that could have appeared to influence the work reported in this  
611 paper.

612

## 613 **Funding**

614 This work is part of the PARIS/SPARTA studies funded by the NIAID Collaborative Influenza Vaccine  
615 Innovation Centers (CIVIC) contract 75N93019C00051.

616

## 617 **Acknowledgments**

618 We thank Margaret Roach, Elizabeth Varghese, Maria Pallin, Celeste Sanchez, and Ailet Reyes for their  
619 technical contributions. We also thank Aria Nawab and Daniel Muniz for their assistance in sample  
620 collection, and Alexander Kizhner for his assistance with data management and in generating the early  
621 statistical analysis.

622

623

## 624 **References**

- 625 1. Wendisch D, Dietrich O, Mari T, von Stillfried S, Ibarra IL, Mittermaier M, et al. SARS-CoV-2  
626 infection triggers profibrotic macrophage responses and lung fibrosis. *Cell*. 2021;184(26):6243-61.e27.
- 627 2. Jacobs JL, Haidar G, Mellors JW. COVID-19: Challenges of Viral Variants. *Annu Rev Med*.  
628 2023;74:31-53.
- 629 3. Shishido AA, Barnes AH, Narayanan S, Chua JV. COVID-19 Vaccines-All You Want to Know.  
630 *Semin Respir Crit Care Med*. 2023;44(1):143-72.
- 631 4. Tsai SC, Lu CC, Bau DT, Chiu YJ, Yen YT, Hsu YM, et al. Approaches towards fighting the  
632 COVID-19 pandemic (Review). *Int J Mol Med*. 2021;47(1):3-22.
- 633 5. Williams EC, Kizhner A, Stark VS, Nawab A, Muniz DD, Echeverri Tribin F, et al. Predictors for  
634 reactogenicity and humoral immunity to SARS-CoV-2 following infection and mRNA vaccination: A  
635 regularized, mixed-effects modelling approach. *Frontiers in Immunology*. 2023;14.
- 636 6. Moshkovits I, Shepshelovich D. Emergency Use Authorizations of COVID-19-Related Medical  
637 Products. *JAMA Intern Med*. 2022;182(2):228-9.
- 638 7. Parums DV. Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2  
639 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy. *Med Sci Monit*.  
640 2021;27:e934625.
- 641 8. Forchette L, Sebastian W, Liu T. A Comprehensive Review of COVID-19 Virology, Vaccines,  
642 Variants, and Therapeutics. *Curr Med Sci*. 2021;41(6):1037-51.
- 643 9. Callegaro A, Borleri D, Farina C, Napolitano G, Valenti D, Rizzi M, et al. Antibody response to  
644 SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection. *J Med*  
645 *Viro*. 2021;93(7):4612-5.
- 646 10. Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, et al. Dynamics of  
647 Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2  
648 Infection. *J Infect Dis*. 2021;223(2):197-205.

- 649 11. Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS-CoV-2  
650 after Covid-19 Vaccination and Previous Infection. *N Engl J Med*. 2022;386(13):1207-20.
- 651 12. Kelsen SG, Braverman AS, Aksoy MO, Hayman JA, Patel PS, Rajput C, et al. SARS-CoV-2  
652 BNT162b2 vaccine-induced humoral response and reactogenicity in individuals with prior COVID-19  
653 disease. *JCI Insight*. 2022;7(4).
- 654 13. Lozano-Ojalvo D, Camara C, Lopez-Granados E, Nozal P, Del Pino-Molina L, Bravo-Gallego  
655 LY, et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in  
656 naive and COVID-19 recovered individuals. *Cell Rep*. 2021;36(8):109570.
- 657 14. Mungmunpantipantip R, Wiwanitkit V. Antibody response to SARS-CoV-2 vaccination,  
658 previous SARS-CoV-2 infection, and change to single-dose vaccination. *J Med Virol*. 2021;93(12):6474.
- 659 15. Nagura-Ikeda M, Imai K, Kubota K, Noguchi S, Kitagawa Y, Matsuoka M, et al. Clinical  
660 characteristics and antibody response to SARS-CoV-2 spike 1 protein using VITROS Anti-SARS-CoV-2  
661 antibody tests in COVID-19 patients in Japan. *J Med Microbiol*. 2021;70(4).
- 662 16. Ontañón J, Blas J, de Cabo C, Santos C, Ruiz-Escribano E, García A, et al. Influence of past  
663 infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers:  
664 Kinetics and durability of the humoral immune response. *EBioMedicine*. 2021;73:103656.
- 665 17. Pereson MJ, Amaya L, Neukam K, Baré P, Echevoyen N, Badano MN, et al. Heterologous gam-  
666 COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than  
667 homologous sputnik V in a real-world data analysis. *Clinical Microbiology and Infection*.  
668 2022;28(10):1382-8.
- 669 18. Tsang JS, Dobaño C, VanDamme P, Moncunill G, Marchant A, Othman RB, et al. Improving  
670 Vaccine-Induced Immunity: Can Baseline Predict Outcome? *Trends Immunol*. 2020;41(6):457-65.
- 671 19. Young KM, Gray CM, Bekker L-G. Is Obesity a Risk Factor for Vaccine Non-Responsiveness?  
672 *PLOS ONE*. 2013;8(12):e82779.

- 673 20. Boroumand AB, Forouhi M, Karimi F, Moghadam AS, Naeini LG, Kokabian P, et al.  
674 Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review. *Frontiers*  
675 *in Immunology*. 2022;13.
- 676 21. Flanagan KL, van Crevel R, Curtis N, Shann F, Levy O, Network ftO. Heterologous  
677 (“Nonspecific”) and Sex-Differential Effects of Vaccines: Epidemiology, Clinical Trials, and Emerging  
678 Immunologic Mechanisms. *Clinical Infectious Diseases*. 2013;57(2):283-9.
- 679 22. Posteraro B, Pastorino R, Di Giannantonio P, Ianuale C, Amore R, Ricciardi W, et al. The link  
680 between genetic variation and variability in vaccine responses: Systematic review and meta-analyses.  
681 *Vaccine*. 2014;32(15):1661-9.
- 682 23. Grubeck-Loebenstien B, Della Bella S, Iorio AM, Michel J-P, Pawelec G, Solana R.  
683 Immunosenescence and vaccine failure in the elderly. *Aging Clinical and Experimental Research*.  
684 2009;21(3):201-9.
- 685 24. Kumar R, Burns EA. Age-related decline in immunity: implications for vaccine responsiveness.  
686 *Expert Review of Vaccines*. 2008;7(4):467-79.
- 687 25. Simon V, Kota V, Bloomquist RF, Hanley HB, Forgacs D, Pahwa S, et al. PARIS and SPARTA:  
688 Finding the Achilles' Heel of SARS-CoV-2. *mSphere*. 2022;7(3):e0017922.
- 689 26. HANC. Cross-Network PBMC Processing Standard Operating Procedure. 2018. p. 1-45.
- 690 27. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al. SARS-  
691 CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and  
692 Test Setup. *Curr Protoc Microbiol*. 2020;57(1):e100.
- 693 28. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A  
694 serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med*. 2020;26(7):1033-6.
- 695 29. Sette A, Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines.  
696 *Immunol Rev*. 2022;310(1):27-46.
- 697 30. Baral S, Sherman SG, Millson P, Beyrer C. Vaccine immunogenicity in injecting drug users: a  
698 systematic review. *Lancet Infect Dis*. 2007;7(10):667-74.



- 699 31. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse.  
700 Clin Microbiol Rev. 2003;16(2):209-19.
- 701 32. Friedman H, Pross S, Klein TW. Addictive drugs and their relationship with infectious diseases.  
702 FEMS Immunology & Medical Microbiology. 2006;47(3):330-42.
- 703 33. Re G-F, Jia J, Xu Y, Zhang Z, Xie Z-R, Kong D, et al. Dynamics and correlations in multiplex  
704 immune profiling reveal persistent immune inflammation in male drug users after withdrawal.  
705 International Immunopharmacology. 2022;107:108696.
- 706 34. Mattson DL, Abais-Battad JM. T Cell Immunometabolism and Redox Signaling in Hypertension.  
707 Curr Hypertens Rep. 2021;23(12):45.
- 708 35. Moshfegh CM, Case AJ. The Redox-Metabolic Couple of T Lymphocytes: Potential  
709 Consequences for Hypertension. Antioxid Redox Signal. 2021;34(12):915-35.
- 710 36. Rai A, Narisawa M, Li P, Piao L, Li Y, Yang G, et al. Adaptive immune disorders in  
711 hypertension and heart failure: focusing on T-cell subset activation and clinical implications. J Hypertens.  
712 2020;38(10):1878-89.
- 713 37. Soegiarto G, Wulandari L, Purnomosari D, Dhia Fahmita K, Ikhwan Gautama H, Tri Hadmoko S,  
714 et al. Hypertension is associated with antibody response and breakthrough infection in health care  
715 workers following vaccination with inactivated SARS-CoV-2. Vaccine. 2022;40(30):4046-56.
- 716 38. Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, et al. Central obesity, smoking  
717 habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA  
718 vaccine. Diabetes Metab Res Rev. 2022;38(1):e3465.
- 719 39. Pellini R, Venuti A, Pimpinelli F, Abril E, Blandino G, Campo F, et al. Initial observations on  
720 age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine.  
721 EClinicalMedicine. 2021;36:100928.
- 722 40. Wolszczak-Biedrzycka B, Bieńkowska A, Dorf J. Assessment of Post-Vaccination Antibody  
723 Response Eight Months after the Administration of BNT162b2 Vaccine to Healthcare Workers with  
724 Particular Emphasis on the Impact of Previous COVID-19 Infection. Vaccines. 2021;9(12):1508.

- 725 41. Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al.  
726 Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *New*  
727 *England Journal of Medicine*. 2021;384(14):1372-4.
- 728 42. Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, Immunity, and COVID-  
729 19: How Age Influences the Host Immune Response to Coronavirus Infections? *Frontiers in Physiology*.  
730 2021;11.
- 731 43. Gustafson CE, Kim C, Weyand CM, Goronzy JJ. Influence of immune aging on vaccine  
732 responses. *Journal of Allergy and Clinical Immunology*. 2020;145(5):1309-21.
- 733 44. Song H, Price PW, Cerny J. Age-related changes in antibody repertoire: contribution from T  
734 cells. *Immunological Reviews*. 1997;160(1):55-62.
- 735 45. Weksler ME. Changes in the B-cell repertoire with age. *Vaccine*. 2000;18(16):1624-8.
- 736 46. Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of  
737 immune system aging. *J Clin Invest*. 2013;123(3):958-65.
- 738 47. Fink AL, Klein SL. The evolution of greater humoral immunity in females than males:  
739 implications for vaccine efficacy. *Curr Opin Physiol*. 2018;6:16-20.
- 740 48. Klein SL, Flanagan KL. Sex differences in immune responses. *Nature Reviews Immunology*.  
741 2016;16(10):626-38.
- 742 49. Ortona E, Pierdominici M, Rider V. Editorial: Sex Hormones and Gender Differences in Immune  
743 Responses. *Front Immunol*. 2019;10:1076.
- 744 50. Kelliher MT, Levy JJ, Nerenz RD, Poore B, Johnston AA, Rogers AR, et al. Comparison of  
745 Symptoms and Antibody Response Following Administration of Moderna or Pfizer SARS-CoV-2  
746 Vaccines. *Arch Pathol Lab Med*. 2022;146(6):677-85.
- 747 51. Keshavarz B, Richards NE, Workman LJ, Patel J, Muehling LM, Canderan G, et al. Trajectory of  
748 IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and  
749 Comparison With Natural Infection. *Frontiers in Immunology*. 2022;13.

## 750 **Supporting information**

751 **S1 Table. Other Measured Extrinsic and Intrinsic Health Factors Among the Primary Vaccination**  
752 **Sub-Cohort. ###: Levene’s test found a statistically significant difference in the variances between**  
753 **participants with and without hypertension ( $F(1,145) = 8.15, p = 0.005$ ).**

754  
755 **S2 Table. Linear Mixed Effects Model (LMM) Evaluating the Relationship Between Post-Primary**  
756 **Vaccination Antibody Titers and Time, COVID-19 Vaccine Manufacturer, Prior COVID-19**  
757 **Infection Status, and Biological Sex.**

758  
759 **S3 Table. Other Measured Extrinsic and Intrinsic Health Factors Among the First Booster**  
760 **Vaccination Sub-Cohort.**

761  
762 **S4 Table. Linear Mixed Effects Model (LMM) Evaluating the Relationship Between BV1 Antibody**  
763 **Titers and Time, COVID-19 Vaccine Manufacturer, Prior COVID-19 Infection Status, and**  
764 **Biological Sex.**

765  
766 **S5 Table. Other Measured Extrinsic and Intrinsic Health Factors Among the Second Booster**  
767 **Vaccination Sub-Cohort.**

768  
769 **S6 Table. Linear Mixed Effects Model (LMM) Evaluating the Relationship Between BV2 Antibody**  
770 **Titers and Time, COVID-19 Vaccine Manufacturer, Prior COVID-19 Infection Status, and**  
771 **Biological Sex.**




Fig1




Fig2




Fig3






Fig4




COVID-19 Vaccine Manufacturer

- Moderna
- Pfizer



COVID Infection Status at Entry

- Positive
- Negative



Biological Sex

- Female
- Male

Fig 5






Fig6